Goodwin Biotechnology, Inc. (GBI) completed the first phase of manufacturing of Neogenix Oncology’s monoclonal antibody, NPC-1C. The product has been delivered to Neogenix in preparation for Phase I/II trials planned for the first half of the year. Neogenix portfolio includes MAbs that recognize cancer-specific immunogenic proteins derived from specific tumor systems. Neogenix monoclonal antibodies define the immunogenic tumor protein as both a diagnostic marker and as a therapeutic target fo...